The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Glucagon-Like Peptide-1 Is Involved in Sodium and Water Homeostasis in Humans
Open accessAbstract
In previous studies with glucagon-like peptide-1 (GLP-1) we have observed that this peptide modulates fluid intake and increases renal sodium excretion in healthy volunteers and in patients with diabetes mellitus type 2. The effect of GLP-1 on thirst, water intake and on osmoregulation has, however, not been examined in detail in humans. Methods: Seventeen healthy male subjects were enrolled in two double-blind, placebo-controlled studies. In study part A, 8 volunteers participated in a protocol with an intravenous salt load of 26.7 ± 0.9 g comparing the effect of an infusion of GLP-1 (1.5 pmol/kg × min) to isotonic saline (placebo). Sodium excretion and water intake were measured. In part B, 9 volunteers were challenged with an oral salt load of 27.7 ± 0.5 g; sodium excretion and water intake were determined comparing an infusion of GLP-1 (1.5 pmol/kg × min) to isotonic saline (placebo). In part C, intestinal biopsies along the gastrointestinal tract were obtained from 14 healthy subjects. Expression of human GLP-1 receptor mRNA was measured by real-time polymerase chain reaction. Results: In study part A, an increase in renal sodium excretion was demonstrated: FeNa rose from 1.6 ± 0.3 (placebo) to 2.7 ± 0.2% (GLP-1; p = 0.0005). There was no difference in water consumption between the two treatments: 1,291 ± 69 (saline) vs. 1,228 ± 74 ml (GLP-1; p = 0.49). In part B, an oral salt challenge of 27.7 ± 0.5 g led to an increased renal excretion of sodium during GLP-1: FeNa increased from 1.6 ± 0.2% (placebo) to 2.0 ± 0.2% (GLP-1; p = 0.012). In contrast to part A, oral water intake was reduced by 36% under GLP-1 treatment: 1,848 ± 331 ml (placebo) vs. 1,181 ± 177 ml (GLP-1; p = 0.0414). Three subjects in part B did not finish treatment with GLP-1 because of diarrhea. Human GLP-1 receptor mRNA expression was highest in the proximal human small intestine compared to terminal ileum and colon (p < 0.02). Conclusions: GLP-1 acts on renal tissue reducing sodium absorption, probably via similar sodium transporters, which also may be localized in the gastrointestinal tract. This hypothesis needs to be confirmed by further studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In one study, osmotic diarrhea occurred 8 h after infusion of GLP-1 peptide (47), and GLP-1RAs have been shown to reduce intestinal uptake of glucose and lipids (48, 49).”
From Safety of Semaglutide (2021) · cites this paper as [47]
In the citing paper
“From a mechanistic standpoint, these results suggest that semaglutide’s effects in suppressing consummatory behaviors are not specific to alcohol and might be driven by its ability to reduce appetite and thirst, such as the need for general fluid intake (55–60), palatability for sweet (taste) (61–64), and/or metabolic energy needs and calorie intake (24, 65–68).”
From The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission (2023) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Renal and intestinal absorptive defects in mice lacking the NHE3 Na+/H+ exchanger
Schultheis, P. J., Clarke, L. L., Meneton, P., Miller, M. L., Soleimani, M., Gawenis, L. R., Riddle, T. M., Duffy, J., Doetschman, T., Wang, T., et al. (1998) · Nature Genetics · doi:10.1038/969 · Cited by 850
Lown, K. S., Mayo, R. R., Leichtman, A. B., Hsiao, H.-L., Turgeon, D. K., Schmiedlin‐Ren, P., Brown, M. B., Guo, W.-S., Rossi, S. J., Benet, L. Z., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90027-8 · Cited by 679
Drucker, D. J. (1998) · Diabetes · doi:10.2337/diab.47.2.159 · Cited by 598
Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Glucagon-like peptide-1: a potent regulator of food intake in humans
Gutzwiller, J.-P., Göke, B., Drewe, J., Hildebrand, P., Ketterer, S., Handschin, D., Winterhalder, R., Conen, D., & Beglinger, C. (1999) · Gut · doi:10.1136/gut.44.1.81 · Cited by 577
Self-citationGutzwiller, J., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 518
Self-citationTaipalensuu, J., Törnblom, H., Lindberg, G., Einarsson, C., Sjöqvist, F., Melhus, H., Garberg, P., Sjöström, B., Lundgren, B., & Artursson, P. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29314-9 · Cited by 444
Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442
Self-citationThe INTERSALT Study: background, methods, findings, and implications
Stamler, J. F. (1997) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/65.2.626s · Cited by 439
Flagged first, then by citations
Cited by
Sorted by citations
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Self-citationFilippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
Crajoinas, R. O., Oricchio, F. T., Pessoa, T. D., Pacheco, B. P. M., Lessa, L. M. A., Malnic, G., & Girardi, A. C. C. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00729.2010 · Cited by 278
Skov, J., Dejgaard, A., Frøkiær, J., Holst, J. J., Jonassen, T., Rittig, S., & Christiansen, J. S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3855 · Cited by 228
Chuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C. N., Koob, G. F., Roberto, M., Vendruscolo, L. F., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.170671 · Cited by 214
Lovshin, J. A., Barnie, A., DeAlmeida, A., Logan, A., Zinman, B., & Drucker, D. J. (2015) · Diabetes Care · doi:10.2337/dc14-1958 · Cited by 168
Carraro‐Lacroix, L. R., Malnic, G., & Girardi, A. C. C. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00082.2009 · Cited by 163
Rieg, T., Gerasimova, M., Murray, F., Masuda, T., Tang, T., Rose, M. A., Drucker, D. J., & Vallon, V. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00259.2012 · Cited by 158
Neuroprotective properties of GLP-1: theoretical and practical applications
Holst, J. J., Burcelin, R., & Nathanson, E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.549466 · Cited by 154
The effect of glucagon-like peptide 1 on cardiovascular risk
Sivertsen, J., Rosenmeier, J. B., Holst, J. J., & Vilsbøll, T. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.211 · Cited by 147
The Cardiovascular Effects of GLP‐1 Receptor Agonists
Okerson, T., & CHILTON, R. J. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00256.x · Cited by 138
Vrang, N., & Larsen, P. J. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.07.003 · Cited by 139
Tonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetologia · doi:10.1007/s00125-016-3938-z · Cited by 126
The potential for renoprotection with incretin-based drugs
Tanaka, T., Higashijima, Y., Wada, T., & Nangaku, M. (2014) · Kidney International · doi:10.1038/ki.2014.236 · Cited by 123
Ogawa, S., Ishiki, M., Nako, K., Okamura, M., Senda, M., Mori, T., & Ito, S. (2011) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.223.133 · Cited by 107
Girardi, A. C. C., Fukuda, L. E., Rossoni, L. V., Malnic, G., & Rebouças, N. A. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00174.2007 · Cited by 99
Effects of glucagon-like peptide-1 receptor agonists on renal function
Filippatos, T. D., & Elisaf, M. S. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i5.190 · Cited by 97
Effects of GLP-1 in the Kidney
Skov, J. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9287-7 · Cited by 95
McKay, N. J., Kanoski, S. E., Hayes, M. R., & Daniels, D. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00472.2011 · Cited by 79
Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation
Hviid, A. V. R., & Sørensen, C. M. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00280.2019 · Cited by 69
von Scholten, B. J., Hansen, T. W., Goetze, J. P., Persson, F., & Rossing, P. R. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.04.004 · Cited by 69
Gupta, S., & Sen, U. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104391 · Cited by 74
Tuttle, K. R., McKinney, T. D., Davidson, J. A., Anglin, G., Harper, K. D., & Botros, F. T. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12816 · Cited by 68
Ninčević, V., Kolarić, T. O., Roguljić, H., Kizivat, T., Smolić, M., & Bilić-Čurčić, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235831 · Cited by 71
Physiology and pathophysiology of incretins in the kidney
von Websky, K., Reichetzeder, C., & Hocher, B. (2013) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000437542.77175.a0 · Cited by 63
GLP-1 based therapies: clinical implications for gastroenterologists
Smits, M. M., van Raalte, D. H., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., & Cahen, D. L. (2016) · Gut · doi:10.1136/gutjnl-2015-310572 · Cited by 62
Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials
Coppolino, G., Leporini, C., Rivoli, L., Ursini, F., Paola, E. D. D., Cernaro, V., Arturi, F., Bolignano, D., Russo, E., Sarro, G. D., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.001 · Cited by 62
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Diamant, M., Nieuwdorp, M., Groen, A. K., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12748 · Cited by 56
McKay, N. J., Galante, D. L., & Daniels, D. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3267-14.2014 · Cited by 55
Crajoinas, R. O., Lessa, L. M. A., Carraro‐Lacroix, L. R., Davel, A. P., Pacheco, B. P. M., Rossoni, L. V., Malnic, G., & Girardi, A. C. C. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00654.2009 · Cited by 55
The role of dietary salt in metabolism and energy balance: Insights beyond cardiovascular disease
Wu, Q., Burley, G., Li, L., Lin, S., & Shi, Y. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14980 · Cited by 59
Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
Zhao, X., Huang, K., Zheng, M., & Duan, J. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0332-5 · Cited by 52
McAdam-Marx, C., White, K. N., & Gurgle, H. E. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s83088 · Cited by 46
Koole, C., Savage, E. E., Christopoulos, A., Miller, L. J., Sexton, P. M., & Wootten, D. L. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1116 · Cited by 43
Blood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies
Lovshin, J. A., & Zinman, B. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.05.001 · Cited by 40
McKay, N. J., & Daniels, D. (2013) · Journal of Neuroendocrinology · doi:10.1111/jne.12086 · Cited by 37
A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia
Winzeler, B., Sailer, C. O., Coynel, D., Zanchi, D., Vogt, D. R., Urwyler, S. A., Refardt, J., & Christ-Crain, M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151800 · Cited by 37
Kedees, M. H., Guz, Y., Grigoryan, M., & Teitelman, G. (2013) · Peptides · doi:10.1016/j.peptides.2013.07.022 · Cited by 35
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Bariatric surgery and hypertension
Bueter, M., Ahmed, A. R., Ashrafian, H., & le Roux, C. W. (2009) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2009.03.218 · Cited by 34
Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers
Winzeler, B., da Conceição, I., Refardt, J., Sailer, C. O., Dutilh, G., & Christ-Crain, M. (2020) · Endocrine · doi:10.1007/s12020-020-02394-2 · Cited by 33
Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases
Xie, W., Song, X., & Liu, Z. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.05.010 · Cited by 33
Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000894 · Cited by 33
Vallon, V., & Docherty, N. G. (2014) · Experimental Physiology · doi:10.1113/expphysiol.2014.078766 · Cited by 31
Vilsbøll, T., & Garber, A. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01579.x · Cited by 30
Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging
Cao, F., Wu, K., Zhu, Y., & Bao, Z.-W. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.731273 · Cited by 34
Gil‐Lozano, M., Romaní‐Pérez, M., Outeiriño‐Iglesias, V., Vigo, E., Brubaker, P. L., González-Matías, L. C., & Mallo, F. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00529.2012 · Cited by 29
Nephroprotective Properties of Antidiabetic Drugs
Gerdes, C., Muller, N., Wolf, G., & Busch, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103377 · Cited by 30
Wan, J., Ferrari, C., & Tadros, M. S. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15010014 · Cited by 32
Savignano, F. A., Crajoinas, R. O., Pacheco, B. P. M., Campos, L. C. G., Shimizu, M. H. M., Seguro, A. C., & Girardi, A. C. C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.054 · Cited by 27
Sodium and water handling after gastric bypass surgery in a rat model
Bueter, M., Ashrafian, H., Frankel, A., Tam, F. W. K., Unwin, R. J., & le Roux, C. W. (2010) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2010.03.286 · Cited by 28
GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes
Chen, T., Hu, E.-H., Chen, D., Lin, Y., Chou, T., Lin, M., Yang, N., Wang, C., Hung, M., & Tsai, M. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.30952 · Cited by 28
Potential Role of Dipeptidyl Peptidase IV in the Pathophysiology of Heart Failure
Salles, T. A., dos SANTOS, L., Baraúna, V. G., & Girardi, A. C. C. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16024226 · Cited by 26
Кутина, А. В., Marina, A. S., Ei, S., & IuV, N. (2013) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12119 · Cited by 25
Effects of liraglutide on hemodynamic parameters in patients with heart failure
Zhang, J. Y., Wang, X. Y., & Wang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.18570 · Cited by 26
Gastrointestinal Symptoms and Diseases Related to Obesity: An Overview
Foxx–Orenstein, A. E. (2010) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2009.12.006 · Cited by 24
on behalf of the Sitagliptin Registry Kinki Cardiologists’ Study (SIRKAS) Investigators, Nakamura, T., Iwanaga, Y., Miyaji, Y., Nohara, R., Ishimura, T., & Miyazaki, S. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0371-z · Cited by 22
Docherty, N. G., & le Roux, C. W. (2014) · Experimental Physiology · doi:10.1113/expphysiol.2014.078790 · Cited by 22
Mikov, M., Pavlović, N., Stanimirov, B., Đanić, M., Goločorbin-Kon, S., Stankov, K., & Al‐Salami, H. (2019) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-019-00570-y · Cited by 23
Arruda-Junior, D. F., Martins, F. L., Dariolli, R., Jensen, L., Antônio, E. L., dos SANTOS, L., Tucci, P. J. F., & Girardi, A. C. C. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00293 · Cited by 20
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Cooper, M. E., & van Raalte, D. H. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194749 · Cited by 24
“Indeed, increased urinary sodium excretion and increased urine volume induced by GLP-1 peptide and its receptor agonists have been confirmed in rodents (25), healthy volunteers (26, 27), insulin-resistant obese males (28, 29), and patients with T2D during acute infusion studies (30).”
Yoshihara, M., Akasaka, H., Ohnishi, H., Miki, T., Furukawa, T., Yuda, S., Saitoh, S., & Miura, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067578 · Cited by 17
Bremholm, L., Andersen, U. B., Hornum, M., Hilsted, L., Veedfald, S., Hartmann, B., & Holst, J. J. (2017) · Physiological Reports · doi:10.14814/phy2.13102 · Cited by 16
Yeung, M. H. Y., Leung, K. L., Choi, L. Y., Yoo, J. S., Yung, S., So, P.-K., & Wong, C.-M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.777395 · Cited by 14
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01036-y · Cited by 18
Li, Y., Lei, R., Lei, H., Qin, X., Xie, F., Yao, C., & Feng, P. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002471 · Cited by 15
Thirst: neuroendocrine regulation in mammals
Todini, L., & Fantuz, F. (2023) · Veterinary Research Communications · doi:10.1007/s11259-023-10104-2 · Cited by 14
Nakhleh, A., Shehadeh, N., & Mansour, B. (2024) · Pituitary · doi:10.1007/s11102-024-01451-7 · Cited by 13
Zheng, W., Chu, C., Lv, Y.-B., Wang, Y., Hu, J., Ma, Q., Yan, Y., Cao, Y.-M., Dang, X.-L., Wang, K., et al. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000484152 · Cited by 12
Brakey, D. J., Schatz, K. C., Paul, M. J., & Daniels, D. (2023) · Physiology & Behavior · doi:10.1016/j.physbeh.2023.114093 · Cited by 12
Baretić, M., Kuŝec, V., & Pavlić-Renar, I. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0517-y · Cited by 13
Mechanisms underpinning remission of albuminuria following bariatric surgery
Nair, M., le Roux, C. W., & Docherty, N. G. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000279 · Cited by 12
Glucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
Krieger, J., Daniels, D., Lee, S. J., Mastitskaya, S., & Langhans, W. (2024) · Comprehensive physiology · doi:10.1002/cph4.7 · Cited by 14
STOLAR, M. W., Chen, S., & Grimm, M. F. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s48837 · Cited by 10
The role of glucagon‑like peptide 1 in glucose homeostasis and in other aspects of human physiology
Franek, E., Gajos, G., Gumprecht, J., Kretowski, A. J., Zahorska‐Markiewicz, B., & Malecki, M. T. (2009) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.829 · Cited by 11
Wang, B., Ni, Y., ZHONG, J., & Sun, F. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00167.x · Cited by 10
Diuretic and Natriuretic Effects of Dipeptidyl Peptidase-4 Inhibitor Teneligliptin
Moroi, M., & Kubota, T. (2015) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000258 · Cited by 9
AGE AND GENDER MAY INFLUENCE THE RESULTS OF ROUX-EN-Y GASTRIC BYPASS? Metabolic syndrome parameters
Andrade-Silva, S. G., Caranti, D. A., Sallet, J. A. A. S., Leal, L. P. F. F., Antonio Joaquim Ferreira, L. E. A. L., & Dâmaso, A. R. (2014) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803201400030002 · Cited by 9
Kanozawa, K., Noguchi, Y., Sugahara, S., Nakamura, S., Yamamoto, H., Kaneko, K., Kono, R., Sato, S., Ogawa, T., Hasegawa, H., et al. (2017) · Clinical and Experimental Nephrology · doi:10.1007/s10157-017-1521-7 · Cited by 10
Shepard, B. D., & ECELBARGER, C. A. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.06.005 · Cited by 7
Sodio, potasio e hipertensión arterial
Zehnder, B. C. (2010) · Revista Médica Clínica Las Condes · doi:10.1016/s0716-8640(10)70566-6 · Cited by 6
Meier, M., Cummings, J. L., Abdelsaid, M. A., Feliciano, J., Eusebe, J., Stirn, H., & Coucha, M. M. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101282 · Cited by 6
The influence of insulin and incretin-based therapies on renal tubular transport
Rosati, E., Giuseppe, G. D., Mezza, T., & Ferraro, P. M. (2024) · Journal of Nephrology · doi:10.1007/s40620-024-02048-w · Cited by 6
Effects of exenatide on glycemia and renal water and ion excretion differ in frogs and rats
Кутина, А. В., Marina, A. S., & Natochin, Y. V. (2016) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093016030054 · Cited by 5
Effektive antidiabetische Therapie zur Vorbeugung einer diabetischen Nephropathie
Muller, N., Busch, M., Gerdes, C., & Wolf, G. (2023) · Nephrologie aktuell · doi:10.1055/a-2055-3322 · Cited by 5
Effects of GLP-1 receptor agonists on copeptin in euvolemic participants
Leibnitz, S., Winzeler, B. F., Refardt, J. C., Vogt, D., Sailer, C. O., & Christ‐Crain, M. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag005 · Cited by 5
Halter, B., Chowdhury, V. S., Gilbert, E. R., & Cline, M. A. (2020) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/j.cbpa.2020.110721 · Cited by 4
Gullaksen, S., Vernstrøm, L., Sørensen, S. S., Ringgaard, S., Laustsen, C., Birn, H., Funck, K. L., Poulsen, P. L., & Laugesen, E. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108673 · Cited by 7
The mechanism of glucagon-like peptide-1 participation in the osmotic homeostasis
Natochin, Y. V., Marina, A. S., Кутина, А. В., Balbotkina, E. V., & Karavashkina, T. A. (2016) · Doklady Biological Sciences · doi:10.1134/s0012496616040086 · Cited by 3
Vukajlovic, T., Sailer, C. O., Asmar, A., Jensen, B. L., Vogt, D., Christ‐Crain, M., & Winzeler, B. F. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac063 · Cited by 4
Nielsen, G. L., Hellström, P. M., Olesen, S. S., & Drewes, A. M. (2026) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2026.2661978 · Cited by 2
Qiu, L., Liu, J., & Hu, N. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1870649 · Cited by 4
Contemporary management of patients with Type 2 diabetes
McAdam-Marx, C., Gaebler, J. A., Bellows, B. K., & Brixner, D. I. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.62 · Cited by 2
A novel natriuretic factor in hypervolemia
Кутина, А. В., Marina, A. S., & IuV, N. (2011) · Doklady Biological Sciences · doi:10.1134/s001249661106010x · Cited by 2
Swapnil, H., Knoll, G. A., Kayibanda, J. F., Fergusson, D. A., Chow, B. J. W., Shabana, W. M., Murphy, E. S., Ramsay, T., James, M. T., White, C. A., et al. (2015) · Canadian Journal of Kidney Health and Disease · doi:10.1186/s40697-015-0048-7 · Cited by 2
Metadata
- Authors
- Gutzwiller, J.-P., Hruz, P., Huber, A. R., Hamel, C., Zehnder, C., Drewe, J., Gutmann, H., Stanga, Z., Vogel, D., & Beglinger, C.
- Affiliations
- Kantonsspital Aarau (CH)
- Clínica Las Condes (CL)
- University Hospital of Basel (CH)
- University Hospital of Bern (CH)
- Venue
- Digestion
- Publisher
- S. Karger AG
- Published
- 2006
- Volume
- 73
- Issue
- 2-3
- Pages
- 142-150
- ISSN
- 0012-2823 (ISSN-L)
- 1421-9867
- OpenAlex
- W2059555444
- Cited by
- 127
- References
- 23
- Citations by year
- 2026: 10 · 2025: 6 · 2024: 5 · 2023: 7 · 2022: 5 · 2021: 4 · 2020: 2 · 2019: 8 · 2018: 2 · 2017: 7 · 2016: 12 · 2015: 9 · 2014: 10 · 2013: 13 · 2012: 3
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Digestion (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion, other-oa)
- Open Access CRIS of the University of Bern
- Funders
- National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Electrolyte and hormonal disorders
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon-like peptide-1, sodium homeostasis, water homeostasis, thirst, water intake, renal sodium excretion, osmoregulation, salt loading, gastrointestinal tract, type 2 diabetes, fluid intake regulation, GLP-1 receptor antagonists, vasopressin
- MeSH terms
- Adult, Analysis of Variance, Blood Glucose, Body Water, Double-Blind Method, Homeostasis, Humans, Male, Natriuresis, Sodium, Thirst, Area Under Curve, Reverse Transcriptase Polymerase Chain Reaction, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review